Literature DB >> 26484405

GLUCAGON PRESCRIPTION PATTERNS IN PATIENTS WITH EITHER TYPE 1 OR 2 DIABETES WITH NEWLY PRESCRIBED INSULIN.

Beth D Mitchell, Xuanyao He, Ian M Sturdy, Andrew P Cagle, Julie A Settles.   

Abstract

OBJECTIVE: To describe glucagon prescription patterns in patients with type 1 (T1DM) or type 2 diabetes (T2DM) who received an initial insulin prescription.
METHODS: Retrospective analyses were conducted with data from Truven Health MarketScan databases to assess time to glucagon prescriptions: filled within 1.5 months after index date (early) or after 1.5 months postindex (nonearly). The index date was the date of first insulin prescription between January 1, 2009 and December 31, 2011; for T2DM, without an insulin prescription in the previous 6 months; for T1DM, diabetes diagnosis preindex or within 3 months postindex.
RESULTS: Analysis included 8,814 patients with T1DM and 47,051 with T2DM (49.3% and 2.4%, respectively) who had glucagon prescriptions filled. The median times to first glucagon prescription were 196 days (T1DM) and 288 days (T2DM). The rates of filling glucagon were highest in the first 1.5 months. The times to first hypoglycemia-related emergency room (ER) visit for T1DM and T2DM cohorts were initially similar for those with early glucagon versus nonearly glucagon prescriptions. After 10.8 and 2.5 months postindex, respectively, the percentage of hypoglycemia-related ER visits was lower for those with early glucagon prescriptions.
CONCLUSION: Glucagon prescriptions filled for patients with diabetes who are initiating insulin are low. Patients with T1DM who were younger and healthier filled glucagon prescriptions more often; patients with T2DM who were younger and sicker and had a higher percentage of hypoglycemia-related ER visit history filled glucagon prescriptions more often. Glucagon filled early was associated with a lower incidence of hypoglycemia-related ER visits.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 26484405     DOI: 10.4158/EP15831.OR

Source DB:  PubMed          Journal:  Endocr Pract        ISSN: 1530-891X            Impact factor:   3.443


  8 in total

1.  Dasiglucagon-A Next-Generation Glucagon Analog for Rapid and Effective Treatment of Severe Hypoglycemia: Results of Phase 3 Randomized Double-Blind Clinical Trial.

Authors:  Thomas R Pieber; Ronnie Aronson; Ulrike Hövelmann; Julie Willard; Leona Plum-Mörschel; Kim M Knudsen; Benedikte Bandak; Ramin Tehranchi
Journal:  Diabetes Care       Date:  2021-06-01       Impact factor: 19.112

2.  Impact of pharmacist outreach on glucagon prescribing.

Authors:  Nakiya Whitfield; Patrick Gregory; Beiyu Liu; Susan Spratt; Benjamin H Smith
Journal:  J Am Pharm Assoc (2003)       Date:  2022-01-31

3.  Glucagon use by U.S. adults with type 1 and type 2 diabetes.

Authors:  Peter A Kahn; Shuling Liu; Rozalina McCoy; Robert A Gabbay; Kasia Lipska
Journal:  J Diabetes Complications       Date:  2021-02-06       Impact factor: 2.852

4.  Human Factors Usability and Validation Studies of a Glucagon Autoinjector in a Simulated Severe Hypoglycemia Rescue Situation.

Authors:  Virginia Valentine; Brett Newswanger; Steve Prestrelski; Anthony D Andre; Mark Garibaldi
Journal:  Diabetes Technol Ther       Date:  2019-06-20       Impact factor: 6.118

5.  Usability of Nasal Glucagon Device: Partially Randomized Caregiver and Third-Party User Experience Trial with Simulated Administration at a Japanese Site.

Authors:  Toshihiko Aranishi; Yukiko Nagai; Yasushi Takita; Shuyu Zhang; Rimei Nishimura
Journal:  Diabetes Ther       Date:  2019-11-04       Impact factor: 2.945

6.  Comparison of a ready-to-use liquid glucagon injection administered by autoinjector to glucagon emergency kit for the symptomatic relief of severe hypoglycemia: two randomized crossover non-inferiority studies.

Authors:  Mark P Christiansen; Martin Cummins; Steven Prestrelski; Nicole C Close; Anh Nguyen; Khaled Junaidi
Journal:  BMJ Open Diabetes Res Care       Date:  2021-10

7.  A Comparative Study of Dasiglucagon Ready-to-Use Autoinjector and Glucagon Emergency Kit During Rescue from Simulated Severe Hypoglycemia.

Authors:  Naila Celeste Bailey; Jeannett Dimsits; Mette Hammer; David M Kendall; Timothy S Bailey
Journal:  Diabetes Technol Ther       Date:  2021-12-16       Impact factor: 7.337

Review 8.  Update on the management of diabetes in long-term care facilities.

Authors:  Thaer Idrees; Iris A Castro-Revoredo; Alexandra L Migdal; Emmelin Marie Moreno; Guillermo E Umpierrez
Journal:  BMJ Open Diabetes Res Care       Date:  2022-07
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.